Jacques Suzanne
Director/Board Member at CORBUS PHARMACEUTICALS HOLDINGS, INC.
Net worth: 3 M $ as of 2024-03-30
Profile
Jacques Rachelle Suzanne is currently the Director at Corbus Pharmaceuticals, Inc., the Independent Non-Executive Director at uniQure NV, the Independent Director at Corbus Pharmaceuticals Holdings, Inc., the Director at Akari Therapeutics Plc, a Trustee at Alma College, and a Member-Equality Task Force at Alliance for Regenerative Medicine.
Previously, Ms. Suzanne served as the Chief Executive Officer at Enzyvant, Inc., the Chief Executive Officer at Enzyvant Therapeutics, Inc., a Director at Viela Bio, Inc., the Vice President-Business Operations at Baxter International, Inc., the Senior Vice President-Global Complement Franchise at Alexion Pharmaceuticals, Inc., the Vice President-Hematology Marketing at Shire Plc, the Vice President-Business Operations at Baxalta, Inc., and worked as a Financial Auditor at Ernst & Young LLP and Deloitte & Touche LLP.
Ms. Suzanne obtained an undergraduate degree from Alma College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AKARI THERAPEUTICS PLC
10.07% | 2024-04-25 | 1,018,027,792 ( 10.07% ) | 3 M $ | 2023-07-30 |
UNIQURE N.V.
0.02% | 2023-09-14 | 7,929 ( 0.02% ) | 41 231 $ | 2024-03-30 |
| 2024-03-21 | 0 ( -.--% ) | - $ | 2024-03-30 |
Jacques Suzanne active positions
| Companies | Position | Start |
|---|---|---|
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Director/Board Member | 2019-04-07 |
| UNIQURE N.V. | Director/Board Member | 2021-10-20 |
| AKARI THERAPEUTICS, PLC | Director/Board Member | 2022-03-27 |
Corbus Pharmaceuticals, Inc.
 Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corbus Pharmaceuticals, Inc. is engaged in biotechnology services. The company is headquartered in Norwood, MA. | Director/Board Member | 2019-03-31 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Corporate Officer/Principal | - |
| Alma College | Director/Board Member | - |
Former positions of Jacques Suzanne
| Companies | Position | End |
|---|---|---|
Enzyvant, Inc.
 Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The private company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Chief Executive Officer | 2022-03-10 |
| VIELA BIO, INC. | Director/Board Member | 2021-03-14 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2019-01-31 |
| ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Jacques Suzanne
| Alma College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| UNIQURE N.V. | Health Technology |
| AKARI THERAPEUTICS, PLC | Health Technology |
| Private companies | 10 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Enzyvant, Inc.
Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The private company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Enzyvant Therapeutics, Inc.
 Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Enzyvant Therapeutics, Inc. develops biopharmaceutical products. It focuses on developing transformative therapies for rare diseases with high unmet needs. The company is headquartered in Cambridge, MA. | Health Technology |
Corbus Pharmaceuticals, Inc.
Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corbus Pharmaceuticals, Inc. is engaged in biotechnology services. The company is headquartered in Norwood, MA. | Health Technology |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
- Stock Market
- Insiders
- Jacques Suzanne
